Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
about
Structural insights into the antigenicity of myelin oligodendrocyte glycoproteinThe crystal structure of myelin oligodendrocyte glycoprotein, a key autoantigen in multiple sclerosisHuman herpesvirus 6 and multiple sclerosis: systemic active infections in patients with early diseaseInvolvement of tissue plasminogen activator in onset and effector phases of experimental allergic encephalomyelitisTuftsin-driven experimental autoimmune encephalomyelitis recovery requires neuropilin-1.Tuftsin promotes an anti-inflammatory switch and attenuates symptoms in experimental autoimmune encephalomyelitis.Modulation of microglial/macrophage activation by macrophage inhibitory factor (TKP) or tuftsin (TKPR) attenuates the disease course of experimental autoimmune encephalomyelitisImmunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE.T- and B-cell responses to myelin oligodendrocyte glycoprotein in experimental autoimmune encephalomyelitis and multiple sclerosis.Suppression of neuro inflammation in experimental autoimmune encephalomyelitis by glia maturation factor antibody.Homo-β-amino acid containing MBP(85-99) analogs alleviate experimental autoimmune encephalomyelitis.Nogo-receptor 1 deficiency has no influence on immune cell repertoire or function during experimental autoimmune encephalomyelitis.A role for the plasminogen activator system in inflammation and neurodegeneration in the central nervous system during experimental allergic encephalomyelitisGenetic heterogeneity of autoimmune disorders in the nonobese diabetic mouse.MOG cell-based assay detects non-MS patients with inflammatory neurologic disease.Myelin/oligodendrocyte glycoprotein-deficient (MOG-deficient) mice reveal lack of immune tolerance to MOG in wild-type mice.T cell dynamics during induction of tolerance and suppression of experimental allergic encephalomyelitis.Experimental autoimmune encephalomyelitis development is aggravated by Candida albicans infectionDiscovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 functionTime-Dependent Progression of Demyelination and Axonal Pathology in MP4-Induced Experimental Autoimmune Encephalomyelitis.Nuclear export inhibitors avert progression in preclinical models of inflammatory demyelination.Diminished degradation of myelin basic protein by anti-sulfatide antibody and interferon-gamma in myelin from glia maturation factor-deficient miceThymic gene transfer of myelin oligodendrocyte glycoprotein ameliorates the onset but not the progression of autoimmune demyelination.IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitisOn the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunityMast cells are essential for early onset and severe disease in a murine model of multiple sclerosis.A peptide-binding motif for I-A(g7), the class II major histocompatibility complex (MHC) molecule of NOD and Biozzi AB/H miceLimiting multiple sclerosis related axonopathy by blocking Nogo receptor and CRMP-2 phosphorylation.Magnetic resonance imaging reveals therapeutic effects of interferon-beta on cytokine-induced reactivation of rat model of multiple sclerosisKinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice.Endothelial NOS-deficient mice reveal dual roles for nitric oxide during experimental autoimmune encephalomyelitis.Regulatory T cells control strain specific resistance to Experimental Autoimmune ProstatitisAge-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosisMolecular grafting onto a stable framework yields novel cyclic peptides for the treatment of multiple sclerosis.Application of quantitative proteomics technologies to the biomarker discovery pipeline for multiple sclerosis.Genetic analysis of type 1 diabetes: embryonic stem cells as new tools to unlock biological mechanisms in type 1 diabetes.Reactivity pattern and cytokine profile of T cells primed by myelin peptides in multiple sclerosis and healthy individuals.Decreased severity of myelin oligodendrocyte glycoprotein peptide 33 - 35-induced experimental autoimmune encephalomyelitis in mice with a disrupted TCR delta chain gene.Analysis of cis-acting sequences from the myelin oligodendrocyte glycoprotein promoter.Insights into the aetiology and pathogenesis of multiple sclerosis.
P2860
Q24681234-80662B74-CECB-416D-8D30-212675B1FC18Q24685683-9E1425EB-7691-42FB-B643-0E0DA37E3DA1Q28142094-7BE4D93E-2B3C-4FEF-AAD8-AD8057100CCEQ28505308-8E205FDD-0B18-4217-9529-D1C1C0CB9459Q30743356-1D6B7B04-28F8-4FB4-B5AA-DBC31149351FQ31057328-2F213C44-A34E-4DCA-803B-2B2933798046Q33290993-424F62F1-B84C-462E-AE38-8FCFFFF28AB4Q34370120-ED703B0C-B84D-40B3-A187-00F6D264505DQ34398673-C0DC8434-9552-4E64-A512-0FEF376D1114Q34520871-0D437AD4-B7B9-45BD-A36C-95D8F2C6106CQ35040831-F3E3E995-22D7-42A4-86FC-0C61F3FA3B3EQ35067696-B429D9DB-6403-4040-9445-C8621593D828Q35085079-D21207C1-409A-4BB1-9507-4C675D7C864FQ35086874-AE7B8878-4488-4232-A2B8-6C914EBB8D5BQ35208073-C1B1FF42-4A63-4CF1-AE66-B9716C18690AQ35242814-50917BBB-8EB7-4A1E-9B3E-8096CE89BF2BQ35269080-0733110E-BFFC-4F9F-AB24-0299A2C962C2Q35563492-C25ECF2E-B924-4AAF-9070-5B143BF6DF09Q35588337-2C4A6222-C918-4921-AAB6-8E901A4AA48AQ35867011-04A8A357-CA76-478D-828D-54D4A760A3E8Q35910495-55C77D09-6A3A-4E3B-B0F4-D55E33009B98Q36011247-D439F4AD-1F1F-4BA2-97B0-AE2076FAC86DQ36085377-144BF851-AFE2-49DD-A28A-37A1705A43B4Q36281698-A82BADAE-7128-4AEC-BD17-E18E77E28CC6Q36370816-286279AA-E6E0-47C4-B6F9-9E663514BB75Q36375991-3300D6AC-0AE5-47C8-AC87-02A6A4165108Q36377035-4A370AB5-3DF4-4044-8E90-746D0756663FQ36661334-44643F08-FBA5-4933-A6C9-EA6E4554AC36Q36839991-EF02C795-F4D9-4335-B3A1-18479BC84E0BQ36999596-F6B36A9B-918D-4BF5-9946-A3A4BF7EF6F4Q37253355-CFF4E7BE-81B6-4BA7-9F86-D25168E58E9AQ37254342-37735ED0-94ED-4B41-83D5-35B9AE6BF100Q37481523-5ACD6F00-F08E-4906-A240-D0E14452905CQ37503343-E5956FD1-C07B-4403-AB99-B784FC38008EQ38056688-9161B43F-5CF9-4219-B8AE-3DCC504658BBQ38117280-E4D13DF4-27E7-4B6A-88AF-154727EDE8D0Q40821801-B07B09EA-0B9C-41B7-89E5-46707360689DQ40911408-22F1F02A-8F3F-4184-8C30-BC17B42BA0EFQ40945087-7148BA5B-9D5A-40CD-93E5-A36000DB69BCQ41745127-6B11ACE2-1514-4480-9B30-C3EE38A42095
P2860
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
description
1997 nî lūn-bûn
@nan
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
1997年论文
@zh
1997年论文
@zh-cn
name
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
@en
type
label
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
@en
prefLabel
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
@en
P2093
P356
P1476
Myelin oligodendrocyte glycoprotein: a novel candidate autoantigen in multiple sclerosis.
@en
P2093
Bernard CC
Bettadapura J
Ichikawa M
P2888
P356
10.1007/S001090050092
P577
1997-02-01T00:00:00Z